Simultaneous Estimation of Irbesartan and Hydrochlorothiazide in Bulk and Tablet Dosage Form by UV-Spectrophotometry

Authors

  • G. V. S. Kumar Department of Pharmaceutical Analysis, East West College of Pharmacy,#63, I Phase, BEL Layout, Bharathnagar, Vishwaneedam PO, Bangalore, Karnataka, India
  • A. Ramprasad Reddy Department of Pharmaceutical Analysis, East West College of Pharmacy,#63, I Phase, BEL Layout, Bharathnagar, Vishwaneedam PO, Bangalore, Karnataka, India
  • S. B. Puranik Department of Pharmaceutical Analysis, East West College of Pharmacy,#63, I Phase, BEL Layout, Bharathnagar, Vishwaneedam PO, Bangalore, Karnataka, India
  • P. Venkateswari Department of Pharmaceutical Analysis, East West College of Pharmacy,#63, I Phase, BEL Layout, Bharathnagar, Vishwaneedam PO, Bangalore, Karnataka, India
  • K. A. Sridhar Department of Pharmaceutics, East West College of Pharmacy, #63, I Phase, BEL Layout, Bharathnagar, Vishwaneedam PO, Bangalore, Karnataka, India

DOI:

https://doi.org/10.37591/(rrjops).v3i3.940

Abstract

 

The present study describes a simple, accurate, precise and cost-effective UV Spectrophotometric method for the simultaneous estimation of irbesartan and hydrochlorothiazide in bulk and tablet dosage form. The solvent used was methanol and the absorption maxima for irbesartan and hydrochlorothiazide were found to be 250 nm and 270 nm respectively. A linear response was observed in the range of 4–20 μg/mL with a correlation coefficient of 0.998 for irbesartan and 2–10 μg/mL with a correlation coefficient of 0.999 for hydrochlorothiazide respectively. The method was then validated for different parameters like accuracy, precision, sensitivity and linearity as per ICH Q2 guidelines. This method can be used for simultaneous estimation of irbesartan and hydrochlorothiazide in quality control of formulation without interference of excepients. The method was successfully applied to estimation of irbesartan and hydrochlorothiazide in tablet formulations.

Keywords: UV-spectrophotometry, irbesartan, hydrochlorothiazide, method development

Downloads

Published

2021-01-15

Issue

Vol 1-3, No 3 (2010-12)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.